James R. Musick - 11 Nov 2022 Form 3 Insider Report for Vitro Biopharma, Inc.

Role
Chief Science Officer, Director, 10%+ Owner
Signature
/s/ James R. Musick
Issuer symbol
N/A
Transactions as of
11 Nov 2022
Net transactions value
$0
Form type
3
Filing time
14 Nov 2022, 13:28:55 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding Common Stock 2,340,498 11 Nov 2022 Direct
holding Common Stock 22,727,635 11 Nov 2022 By Trust F1
holding Common Stock 2,956,849 11 Nov 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding Employee Stock Option (Right to Buy) 11 Nov 2022 Common Stock 4,300,000 $0.0500 Direct F2
holding Employee Stock Option (Right to Buy) 11 Nov 2022 Common Stock 1,000,000 $0.5000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares are held by the James R. Musick Trust, of which James R. Musick serves as the sole trustee and beneficiary.
F2 The option became exercisable as to (i) 860,000 shares on May 1, 2018, (ii) 860,000 shares on May 1, 2019, (iii) 860,000 shares on May 1, 2020, (iv) 860,000 shares on May 1, 2021, and (v) 860,000 shares on May 1, 2022.
F3 The option became exercisable as to 200,000 shares on November 30, 2021, and will become exercisable as to (i) 200,000 shares on November 30, 2022, (ii) 200,000 shares on November 30, 2023, (iii) 200,000 shares on November 30, 2024 and (iv) 200,000 shares on November 30, 2025.